Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

52.08
+0.25000.48%
Volume:1.98M
Turnover:104.79M
Market Cap:5.04B
PE:-10.94
High:53.67
Open:52.20
Low:52.00
Close:51.83
52wk High:78.48
52wk Low:44.12
Shares:96.69M
Float Shares:93.17M
Volume Ratio:1.82
T/O Rate:2.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7595
EPS(LYR):-6.4700
ROE:-26.09%
ROA:-14.20%
PB:2.88
PE(LYR):-8.05

Loading ...

Danaher’s IDT, Aldevron launch research grade S.p. Cas9 mRNA, SpyFi

TIPRANKS
·
Yesterday

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 08

Arm's Haas: AI Could Cure Cancer In Our Lifetime — If The Industry Can Build Enough Chips

AI Industry Frontlines
·
Sep 08

CRISPR Therapeutics (CRSP) Extends CTX310 Durability, Is The Stock Still Cheap?

Simply Wall St.
·
Sep 03

Investors Shrug Off Good News for Heart Patients from New Meds

Dow Jones
·
Sep 02

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

Simply Wall St.
·
Aug 30

Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair

TIPRANKS
·
Aug 29

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

GlobeNewswire
·
Aug 28

Oculis Q2 Net Loss Narrows Despite Higher Expenses

Reuters
·
Aug 07

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.
·
Aug 06

Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Aug 06

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Reuters
·
Aug 06

RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Aug 06

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Reuters
·
Aug 06

Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo

TIPRANKS
·
Aug 05

Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says

MT Newswires Live
·
Aug 04

Crispr Therapeutics AG Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Crispr Therapeutics Q2 FY26 Net Loss Narrows to $91.2 Million; Casgevy Revenue Rises 151% Year over Year to $76 Million

Reuters
·
Aug 04

CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate

Benzinga Earnings
·
Aug 04

Scribe's Genetic Editing Aims to Prevent Heart Attacks

Dow Jones
·
Jul 30